SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Summary

The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.

Conditions

• Breast Neoplasm
• Breast Cancer
• Hormone Receptor Positive Tumor
• HER2-negative Breast Cancer
• Advanced Breast Cancer

Interventions

DRUG

PIK3CA inhibitor

PIK3CA inhibitor

DRUG

AKT inhibitor

AKT inhibitor

DRUG

Carrelizumab

Pd-1 mab

DRUG

Famitinib

VEGFR inhibitor

DRUG

Fluzoparib

PARP inhibitor

DRUG

Dalpiciclib

CDK4/6 inhibitor

DRUG

SHR-A1811

HER2 ADC

DRUG

Everolimus

mTOR inhibior

DRUG

Aromatase Inhibitors or Fulvestrant

Letrozole/Anastrozole/Exemestane or Fulvestrant

DRUG

Goserelin

For premenopause

DRUG

TPC

Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)

DRUG

Sorafenib

RTK Inhibitor

DRUG

Apatinib

Apatinib 250mg po qd

DRUG

SHR-A1921

TROP2 ADC

DRUG

SHR-A2102

NECTIN4 ADC

DRUG

SHR-A2009

HER3 ADC

DRUG

SHR-1167

PARP1i

DRUG

SHR-6209

CDK4i

DRUG

bevacizumab

bevacizumab

Sponsors & Collaborators

• Peking University Cancer Hospital & Institute

  collaborator OTHER

• First Hospital of China Medical University

  collaborator OTHER

• Sun Yat-sen University

  collaborator OTHER

• First Affiliated Hospital Xi'an Jiaotong University

  collaborator OTHER

• Chongqing University Cancer Hospital

  collaborator OTHER

• Northern Jiangsu People's Hospital

  collaborator OTHER

• Fujian Medical University Union Hospital

  collaborator OTHER

• Ningbo Medical Center Lihuili Hospital

  collaborator OTHER_GOV

• Shanghai First Maternity and Infant Hospital

  collaborator OTHER

• Shanghai 6th People's Hospital

  collaborator OTHER

• Affiliated Hospital of Nantong University

  collaborator OTHER

• Nanchang People's Hospital

  collaborator UNKNOWN

• Liaoning Cancer Hospital & Institute

  collaborator OTHER

• The Affiliated Hospital of Nantong University

  collaborator UNKNOWN

• The First Hospital of Jilin University

  collaborator OTHER

• Fudan University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-12-30

Primary Completion

2025-12-01

Completion

2026-12-01

Countries

• China

Study Locations